Management of Impulse Control and Related Disorders in Parkinson's Disease: An Expert Consensus
Ines Debove,Steffen Paschen,Deborah Amstutz,Francisco Cardoso,Jean‐Christophe Corvol,Victor S.C. Fung,Anthony E. Lang,Pablo Martinez Martin,María C. Rodríguez‐Oroz,Daniel Weintraub,Paul Krack,Günther Deuschl,and the Members of the ICBD in PD Management Consensus Group,Fred Stephen Sarfo,Albert Kwaku Akpalu,Njideka Okubadejo,Ali Soliman Shalash,Nobutaka Hattori,Jee‐Young Lee,Sean O'Sullivan,Angelo Antonini,Roberta Biundo,Albert Leentjens,Odile van den Heuvel,Mathieu Anheim,Juan Carlos Martinez‐Castrillo,Pedro Garcia Ruiz,Melissa Armstrong,Daniel Claassen,Mayela Rodriguez‐Violante,Emilia Gatto,Andrew Evans
DOI: https://doi.org/10.1002/mds.29700
IF: 9.698
2024-01-18
Movement Disorders
Abstract:Impulse control and related behavioral disorders (ICBDs) are common in Parkinson's disease (PD) and can profoundly affect patients and caregivers if left undiagnosed and untreated.An international expert consensus defined ICBD severity, recommended general treatment guidelines, and outlined first‐line and subsequent treatment strategies, including cognitive‐behavior therapy, subthalamic nucleus deep brain stimulation (STN DBS), and various medication options. Tailored treatment pathways were suggested for motor symptom exacerbation due to dopamine medication reduction, punding, and dopamine dysregulation syndrome (DDS). The importance of further research in ICBD management was underscored. Impulse control and related behavioral disorders (ICBDs) are common in Parkinson's disease, significantly impacting patients and caregivers when untreated. An international expert consensus defined ICBD severity, recommended general treatment recommendations, including 1st line and subsequent further therapy strategies. Tailored treatment pathways for motor symptom exacerbation, punding, and DDS were proposed. Background Impulse‐control and related behavioral disorders (ICBDs) significantly impact the lives of Parkinson's disease (PD) patients and caregivers, with lasting consequences if undiagnosed and untreated. While ICBD pathophysiology and risk factors are well‐studied, a standardized severity definition and treatment evidence remain elusive. Objective This work aimed to establish international expert consensus on ICBD treatment strategies. To comprehensively address diverse treatment availabilities, experts from various continents were included. Methods From 2021 to 2023, global movement disorders specialists engaged in a Delphi process. A core expert group initiated surveys, involving a larger panel in three iterations, leading to refined severity definitions and treatment pathways. Results Experts achieved consensus on defining ICBD severity, emphasizing regular PD patient screenings for early detection. General treatment recommendations focused on continuous monitoring, collaboration with significant others, and seeking specialist advice for legal or financial challenges. For mild to severe ICBDs, gradual reduction in dopamine agonists was endorsed, followed by reductions in other PD medications. Second‐line treatment strategies included diverse approaches like reversing the last medication change, cognitive behavior therapy, subthalamic nucleus deep brain stimulation, and specific medications like quetiapine, clozapine, and antidepressants. The panel reached consensus on distinct treatment pathways for punding and dopamine dysregulation syndrome, formulating therapy recommendations. Comprehensive discussions addressed management strategies for the exacerbation of either motor or non‐motor symptoms following the proposed treatments. Conclusion The consensus offers in‐depth insights into ICBD management, presenting clear severity criteria and expert consensus treatment recommendations. The study highlights the critical need for further research to enhance ICBD management. © 2024 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
clinical neurology